Patton Albertson Miller Group LLC Sells 1,616 Shares of Elevance Health, Inc. $ELV

Patton Albertson Miller Group LLC reduced its holdings in Elevance Health, Inc. (NYSE:ELV) by 66.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 799 shares of the company’s stock after selling 1,616 shares during the quarter. Patton Albertson Miller Group LLC’s holdings in Elevance Health were worth $258,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Janney Montgomery Scott LLC raised its holdings in Elevance Health by 0.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 48,049 shares of the company’s stock worth $18,689,000 after purchasing an additional 272 shares in the last quarter. PFG Investments LLC increased its position in shares of Elevance Health by 5.2% during the second quarter. PFG Investments LLC now owns 1,408 shares of the company’s stock valued at $548,000 after buying an additional 70 shares during the period. Consolidated Planning Corp bought a new position in Elevance Health in the second quarter worth about $235,000. Pure Financial Advisors LLC lifted its holdings in Elevance Health by 39.3% in the second quarter. Pure Financial Advisors LLC now owns 2,749 shares of the company’s stock worth $1,069,000 after buying an additional 776 shares during the period. Finally, J. Safra Sarasin Holding AG lifted its holdings in Elevance Health by 69.9% in the second quarter. J. Safra Sarasin Holding AG now owns 33,564 shares of the company’s stock worth $13,055,000 after buying an additional 13,804 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Trading Down 0.4%

Elevance Health stock opened at $345.62 on Friday. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The company has a market capitalization of $76.81 billion, a price-to-earnings ratio of 13.76, a price-to-earnings-growth ratio of 1.88 and a beta of 0.51. The business’s fifty day simple moving average is $351.69 and its two-hundred day simple moving average is $329.03. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is 27.23%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wall Street Zen upgraded Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Leerink Partners upped their price target on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research note on Thursday. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Robert W. Baird upped their target price on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, Truist Financial set a $400.00 price target on shares of Elevance Health in a research note on Tuesday, October 14th. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and a consensus price target of $398.16.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.